zoledronic acid has been researched along with temozolomide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bowersock, J; Dasgupta, A; Gillespie, GY; Johnson, A; Lamb, LS; Spencer, HT; Su, Y | 1 |
| Fukai, J; Koizumi, F; Nakao, N | 1 |
| Artuso, S; Balestrieri, ML; Caraglia, M; De Rosa, G; Leonetti, C; Luce, A; Lusa, S; Porru, M; Salzano, G; Stoppacciaro, A; Zappavigna, S | 1 |
1 review(s) available for zoledronic acid and temozolomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for zoledronic acid and temozolomide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytotoxicity, Immunologic; Dacarbazine; Diphosphonates; Drug Resistance, Neoplasm; Flow Cytometry; Genetic Engineering; Genetic Vectors; Glioblastoma; GPI-Linked Proteins; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Interleukin-2; Lentivirus; O(6)-Methylguanine-DNA Methyltransferase; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Temozolomide; Zoledronic Acid | 2013 |
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diphosphonates; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Imidazoles; Mice; O(6)-Methylguanine-DNA Methyltransferase; ras Proteins; Signal Transduction; Temozolomide; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |
Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Dacarbazine; Diphosphonates; Drug Delivery Systems; Drug Resistance, Neoplasm; Glioblastoma; Humans; Imidazoles; Male; Mice; Mice, Inbred Strains; Nanoparticles; Nitrosourea Compounds; Organophosphorus Compounds; Temozolomide; Transferrin; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2014 |